UnitedHealth Group Incorporated (UNH)

FairStock Score: 46/100 — MIXED

Key Financials

Strengths

• Strong free cash flow generation of $13.9B annually demonstrates underlying operational cash conversion
• Diversified revenue streams across insurance, care delivery, pharmacy, and data analytics reduce single-point-of-failure risk
• Low beta of 0.38 provides defensive portfolio characteristics during market volatility
• Market leadership position with 390,000 employees and significant scale advantages
• Growing healthcare IT/data analytics segment (Optum Insight) provides higher-margin growth avenue

Concerns

• Valuation is divorced from reality: P/E of 20.83 with Graham Number of $4.83 represents massive overvaluation
• Latest quarter shows near-zero profitability (0.01% net margin) despite $113B revenue, indicating margin compression or one-time charges
• Poor capital returns: ROE of 12.54% and ROCE of 3.90% suggest inefficient capital deployment
• Distressed financial position indicated by Altman Z-Score of 1.45 combined with D/E ratio of 0.82 and weak Piotroski F-Score of 5/9
• EV/EBITDA of 226.33 is indefensible; this suggests either earnings collapse or massive impairment risks ahead

AI Analysis

UnitedHealth Group presents a paradox that troubles me deeply. On the surface, we see a behemoth with $256 billion in market capitalization, generating $13.9 billion in free cash flow annually—the kind of cash generation that Graham would respect. The business operates across four segments: insurance, care delivery, pharmacy, and data analytics, which provides diversification I appreciate. The low beta of 0.38 suggests defensive characteristics suitable for risk-averse portfolios. However, the valuation metrics scream caution. A P/E of 20.83 combined with a Graham Number of just $4.83 creates a margin of safety of negative 5,745%—meaning we're paying 11,700 times what intrinsic value suggests. The latest quarter reveals a net income margin of 0.01% on $113.2 billion revenue—essentially breakeven profitability despite enormous scale. The Piotroski F-Score of 5/9 indicates mixed financial quality, while the Altman Z-Score of 1.45 places the company in the distress zone. Most alarming: an EV/EBITDA of 226.33 is astronomical for a mature healthcare operator. This isn't a business trading at reasonable prices; it's a speculation on perpetual growth. The ROE of 12.54% is mediocre for required capital, and ROCE of 3.90% is frankly poor. I see a highly leveraged business (D/E of 0.82) trading at bubble valuations, vulnerable to regulatory headwinds in healthcare and economic cycles.

Bull Case

UnitedHealth's diversification into high-margin data analytics (Optum Insight) and integrated care delivery positions it to capture value as healthcare consolidates. The company's $13.9B annual free cash flow and defensive business model could support dividend growth and buybacks, rewarding patient shareholders long-term despite current valuation concerns.

Bear Case

The 0.01% net margin in the latest quarter combined with distressed financial metrics (Z-Score 1.45, ROCE 3.90%) suggests fundamental deterioration. Regulatory pressure on healthcare insurers, economic slowdown reducing premium volumes, and the unjustifiable 226x EV/EBITDA multiple create a perfect storm for significant downside if sentiment shifts.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer